D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR 0.82% Market Closed
Market Cap: 1.2B MYR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one DPHARMA stock under the Base Case scenario is 1.94 MYR. Compared to the current market price of 1.23 MYR, Duopharma Biotech Bhd is Undervalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DPHARMA Relative Value
Base Case
1.94 MYR
Undervaluation 36%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
96
vs Industry
60
Median 3Y
1.7
Median 5Y
1.9
Industry
2.4
Forward
1.4
More Details
21.1
P/E
P/E
Price to Earnings
21.1
vs History
58
vs Industry
22
Median 3Y
20.9
Median 5Y
21.6
Industry
20.5
Forward
17.7
More Details
12.6
P/OCF
P/OCF
Price to OCF
12.6
vs History
90
vs Industry
32
Median 3Y
22.2
Median 5Y
23.5
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
29
Median 3Y
10.8
Median 5Y
37.3
Industry
22.6
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
87
vs Industry
44
Median 3Y
1.8
Median 5Y
2
Industry
2
More Details
1.8
EV/S
EV/S
Enterprise Value to Sales
1.8
vs History
92
vs Industry
54
Median 3Y
2
Median 5Y
2.1
Industry
2.5
Forward
1.7
More Details
4.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.9
vs History
76
vs Industry
40
Median 3Y
5.3
Median 5Y
5.4
Industry
4.9
More Details
10.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.1
vs History
82
vs Industry
32
Median 3Y
11.3
Median 5Y
11.7
Industry
12.6
Forward
9.6
More Details
15.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.5
vs History
71
vs Industry
27
Median 3Y
16.6
Median 5Y
17.3
Industry
15.6
Forward
13.6
More Details
14.9
EV/OCF
EV/OCF
Enterprise Value to OCF
14.9
vs History
88
vs Industry
28
Median 3Y
26.1
Median 5Y
26.9
Industry
13.9
More Details
21.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
21.7
vs History
49
vs Industry
21
Median 3Y
-21.1
Median 5Y
21.5
Industry
17.7
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
82
vs Industry
45
Median 3Y
1.4
Median 5Y
1.6
Industry
1.8
More Details

Multiples Across Competitors

DPHARMA Competitors Multiples
Duopharma Biotech Bhd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
MY
Duopharma Biotech Bhd
KLSE:DPHARMA
1.2B MYR 1.5 21.1 10.1 15.5
US
Eli Lilly and Co
NYSE:LLY
807.6B USD 17.9 76.3 44.3 48.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
387.6B USD 4.4 27.6 12.9 16.9
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.7 22.1 14.6 16.6
CH
Roche Holding AG
SIX:ROG
242B CHF 4.1 21 11.7 13.9
UK
AstraZeneca PLC
LSE:AZN
174.6B GBP 4.2 32.1 126.8 193.6
CH
Novartis AG
SIX:NOVN
196B CHF 4.3 18.6 11.2 14.4
US
Merck & Co Inc
NYSE:MRK
222.5B USD 3.5 13 8.8 10.4
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
144.8B USD 2.3 18 8.6 12.3
P/E Multiple
Earnings Growth PEG
MY
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Average P/E: 27.8
21.1
22%
1
US
Eli Lilly and Co
NYSE:LLY
76.3
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.6
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
22.1
19%
1.2
CH
Roche Holding AG
SIX:ROG
21
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
32.1
36%
0.9
CH
Novartis AG
SIX:NOVN
18.6
16%
1.2
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
18
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
MY
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Average EV/EBITDA: 396.6
10.1
16%
0.6
US
Eli Lilly and Co
NYSE:LLY
44.3
30%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.9
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
15%
1
CH
Roche Holding AG
SIX:ROG
11.7
8%
1.5
UK
AstraZeneca PLC
LSE:AZN
126.8
9%
14.1
CH
Novartis AG
SIX:NOVN
11.2
5%
2.2
US
Merck & Co Inc
NYSE:MRK
8.8
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.6
3%
2.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
MY
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Average EV/EBIT: 1 701.4
15.5
23%
0.7
US
Eli Lilly and Co
NYSE:LLY
48.9
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.9
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
16.6
16%
1
CH
Roche Holding AG
SIX:ROG
13.9
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.6
21%
9.2
CH
Novartis AG
SIX:NOVN
14.4
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.3
10%
1.2

See Also

Summary
DPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
DPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DPHARMA stock valuation using valuation multiples.
Wall Street Estimates
DPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.